← Back to Home

Efficacy outlook falls short of interim threshold as Teva stops Phase 2 trial in multiple system atrophy

Emrusolmin aims to prevent disease-related protein aggregation, but its trial has now been stopped because of a low probability of meeting the primary efficacy endpoint. The interim analysis identified no safety concerns, but the future of the overall development program awaits complete data.

By SURL BioNews

For patients with multiple system atrophy, whether a drug can slow functional decline is a question new therapies must answer. On November 2, Teva announced that it was stopping the Phase 2 TOPAS-MSA trial of its oral drug candidate emrusolmin: a preplanned interim analysis showed a low probability of meeting the primary efficacy endpoint even if the study continued.

The decision followed a recommendation from an independent data monitoring committee. Teva emphasized that this was a predictive futility analysis, not a final efficacy analysis; the interim data also identified no safety concerns. The direct reason for stopping the trial was that the efficacy outlook did not meet the prespecified threshold, rather than an identified safety issue.

TOPAS-MSA used a randomized, double-blind, placebo-controlled design and originally planned to enroll approximately 350 adults to receive 300 milligrams of emrusolmin or placebo for approximately 48 weeks. The primary endpoint was the change from baseline at week 48 in Part I of the modified Unified Multiple System Atrophy Rating Scale; the planned enrollment cannot be treated as the number of participants who actually completed treatment.

Multiple system atrophy is a rare neurodegenerative disease that can affect both motor and autonomic function, causing problems with gait, coordination, blood pressure regulation, or bladder function. Its pathological features include abnormal deposits of α-synuclein. Emrusolmin, jointly developed by Teva and MODAG, is designed to interfere with the aggregation of this protein, but the proposed mechanism of action still requires validation through human efficacy data.

The current announcement does not provide the efficacy difference between the two groups, the number of participants included in the interim analysis, or the numerical futility threshold, so it is not yet possible to determine how far the drug's effect fell short of the trial's requirements. “No safety concerns identified” also describes only this interim assessment and cannot be taken to mean that long-term safety has been confirmed.

Teva will next analyze the complete trial data, along with available results from a separate open-label extension study, before assessing the overall emrusolmin program. The extension study focuses on long-term safety and tolerability, and its interpretation must still account for the limitations arising from the lack of blinding and a placebo control. This announcement confirms that TOPAS-MSA is being stopped; a final decision on the overall drug development program has yet to be made.

References

  1. Teva Pharmaceuticals